China Allergy Immunotherapy Market Size & Outlook
The allergy immunotherapy market in China is expected to reach a projected revenue of US$ 30.5 million by 2027. A compound annual growth rate of 13.8% is expected of China allergy immunotherapy market from 2020 to 2027.
Revenue, 2019 (US$M)
$10.8
Forecast, 2027 (US$M)
$30.5
CAGR, 2020 - 2027
13.9%
Report Coverage
China
China allergy immunotherapy market, 2016-2027 (US$M)
Related Markets
China allergy immunotherapy market highlights
- The China allergy immunotherapy market generated a revenue of USD 10.8 million in 2019 and is expected to reach USD 30.5 million by 2027.
- The China market is expected to grow at a CAGR of 13.8% from 2020 to 2027.
- In terms of segment, subcutaneous immunotherapy was the largest revenue generating treatment type in 2019.
- Subcutaneous immunotherapy is the most lucrative treatment type segment registering the fastest growth during the forecast period.
Allergy immunotherapy market data book summary
| Market revenue in 2019 | USD 10.8 million |
| Market revenue in 2027 | USD 30.5 million |
| Growth rate | 13.8% (CAGR from 2019 to 2027) |
| Largest segment | Subcutaneous immunotherapy |
| Fastest growing segment | Subcutaneous immunotherapy |
| Historical data | 2016 - 2018 |
| Base year | 2019 |
| Forecast period | 2020 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Subcutaneous immunotherapy, Sublingual immunotherapy |
| Key market players worldwide | Merck KGaA, Allergy Therapeutics PLC, DBV Technologies SA ADR, ASIT biotech, Circassia, Mylan, DMK Pharmaceuticals Corp, Alk-Abello A/S Class B, Desentum, HAL Allergy Group, HollisterStier Allergy, Stallergenes Greer |
Other key industry trends
- In terms of revenue, China accounted for 0.7% of the global allergy immunotherapy market in 2019.
- Country-wise, Germany is expected to lead the global market in terms of revenue in 2027.
- In Asia Pacific, Japan allergy immunotherapy market is projected to lead the regional market in terms of revenue in 2027.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 30.5 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Allergy Immunotherapy Market Scope
Allergy immunotherapy market segmentation & scope
Allergy Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China allergy immunotherapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to allergy immunotherapy market will help companies and investors design strategic landscapes.
Subcutaneous immunotherapy was the largest segment with a revenue share of 50% in 2019. Horizon Databook has segmented the China allergy immunotherapy market based on subcutaneous immunotherapy, sublingual immunotherapy covering the revenue growth of each sub-segment from 2016 to 2027.
- China Allergy Immunotherapy Treatment Type Outlook (Revenue, USD Million, 2016-2027)
- Subcutaneous immunotherapy
- Sublingual immunotherapy
- Tablets
- Drops
- China Allergy Immunotherapy Allergy Type Outlook (Revenue, USD Million, 2016-2027)
- Allergic Rhinitis
- Allergic Asthma
- Other Allergies
- China Allergy Immunotherapy Distribution Channel Outlook (Revenue, USD Million, 2016-2027)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Reasons to subscribe to China allergy immunotherapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China allergy immunotherapy market databook
-
Our clientele includes a mix of allergy immunotherapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China allergy immunotherapy market, including forecasts for subscribers. This country databook contains high-level insights into China allergy immunotherapy market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
China allergy immunotherapy market size, by treatment type, 2016-2027 (US$M)
China Allergy Immunotherapy Market Share, 2019 & 2027 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
